COSTA MESA, Calif., Jan. 15 /PRNewswire-FirstCall/ — CNS Response, Inc. (BULLETIN BOARD: CNSO) announced today that it has completed the previously announced acquisition of Neuro-Therapy Clinic, P.C., a neuropsychiatric clinic in Denver, Colorado. The Company also announced that Daniel A. Hoffman, MD has been appointed Chief Medical Officer. Dr. Hoffman, a neuropsychiatrist with more than 25 years experience, was previously National Medical Director of Neuro-Therapy Clinic.
Len Brandt, Chairman and CEO of CNS Response, reported, “Our close relationship with Dr. Hoffman and the Neurotherapy Clinic has already played a significant role in establishing the value of rEEG(R) guidance in medication management.”
George Carpenter, President of CNS Response, commenting on the future, said, “We expect Neuro-Therapy Clinic to further define the opportunity to use technology in general, and rEEG in particular, to vastly improve clinic performance in patient outcomes, costs, and convenience and to best communicate this to all — patient, physician, payer. In this way, the Neuro-Therapy Clinic is something of a dynamic laboratory discovering how to integrate technology and be a true center of excellence on all of these measures. Put to practice, this knowledge presents CNS Response with an opportunity to further our relationship with other clinics and physicians using rEEG.”
“Dr. Hoffman is a leader and a true partner in the development of rEEG so we are particularly pleased to have him join our team,” Mr. Brandt continued. “Dr. Hoffman will play a critical role in implementing our strategy for the validation and commercialization of our core rEEG platform.”
Established in 1993, Neuro-Therapy Clinic, P.C. is a center for highly-advanced testing and treatment of neuropsychiatric problems, including learning, attentional and behavioral challenges, mild head injuries, as well as depression, anxiety, bipolar and all other common psychiatric disorders.
Dr. Hoffman served as Medical Director for Neuro-Therapy Clinic from 1993-2007. He also served as National Medical Director for CNS Response from 2004-2007 and has maintained a private practice in neuropsychiatry since 1977. He served as an Assistant Clinical Professor at the University of Colorado from 1977 to 1996.
Dr. Hoffman has lectured extensively throughout the country on leading-edge testing and treatment for Psychiatric Medication Selection and other brain related topics and has been published in more than 30 peer-reviewed articles. He is on the editorial boards of the Journal of Neurotherapy, the Journal of Applied Psychophysiology and Self Regulation and the Journal of Neuropsychiatry and Clinical Neurosciences.
About CNS Response
CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports (“rEEG(R) Reports”) that specifically guide physicians to treatment strategies based on the patient’s own physiology.
rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company’s filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Contacts: Investor Relations: Sara Ephraim (646) 536-7002 [email protected] Media: Jason Rando / Jennifer Saunders (646) 536-7033 / 7011 [email protected] [email protected]
CNS Response, Inc.
CONTACT: Investor Relations: Sara Ephraim, +1-646-536-7002,[email protected], or Media: Jason Rando, +1-646-536-7033,[email protected], or Jennifer Saunders, +1-646-536-7011,[email protected], all of The Ruth Group, for CNS Response, Inc.
Web site: http://www.cnsresponse.com/
Comments